Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma

The Oncologist
Adil Daud, Katy Tsai

Abstract

Tremendous progress has been made in the clinical landscape of advanced-stage BRAF V600-mutant melanoma treatment over the past 5 years. Targeted therapies that inhibit specific steps of the mitogen-activated protein kinase pathway have been shown to provide significant overall treatment benefit in patients with this difficult-to-treat disease. Combination therapy with BRAF and MEK inhibitors (dabrafenib plus trametinib or vemurafenib plus cobimetinib, respectively) has become standard of care. These agents are administered until disease progression or unacceptable toxicity occurs; thus, some patients may remain on maintenance therapy for an extended period of time, while toxicities may result in early discontinuation in other patients. Because the goal of treatment is to prolong survival with minimal impairment of quality of life, drug-related adverse events (AEs) require prompt management to ensure that patients derive the best possible benefit from therapy. Proper management depends on an understanding of which AEs are most likely BRAF or MEK inhibitor associated, thus providing a rationale for dose modification of the appropriate drug. Additionally, the unique safety profile of the chosen regimen may influence patient selec...Continue Reading

References

Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Dec 30, 2006·Biochimica Et Biophysica Acta·Ding WangPatricia M LoRusso
Nov 26, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Wenhu HuangHusam S Younis
Jan 9, 2010·Circulation Research·Hui Cheng, Thomas Force
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Feb 3, 2012·The New England Journal of Medicine·Reinhard DummerSimone M Goldinger
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Feb 26, 2013·Cancer Treatment Reviews·Ruud van der NollJan H M Schellens
Mar 5, 2013·The Oncologist·Mario E LacoutureAndrew K Joe
Apr 5, 2013·Case Reports in Ophthalmological Medicine·Scott D Schoenberger, Stephen J Kim
May 29, 2013·Nature Reviews. Clinical Oncology·Geoffrey T GibneyKeiran S M Smalley
Oct 8, 2013·Cancer Research·Meghna Das Thakur, Darrin D Stuart
Oct 25, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Stéphanie Marie BoudonDaniel Bauer
Dec 3, 2013·BMC Cancer·Sanne E J WolfMichiel S van der Heijden
Jan 30, 2014·Case Reports in Ophthalmology·Lavnish JoshiSimon R J Taylor
May 28, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U Urner-BlochS M Goldinger
Jun 25, 2014·Nature Reviews. Cancer·Matthew HolderfieldMartin McMahon
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Siwen Hu-LieskovanAntoni Ribas
Sep 30, 2014·The New England Journal of Medicine·Georgina V LongKeith Flaherty
Sep 30, 2014·The New England Journal of Medicine·James LarkinAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Nov 21, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M MenziesA Daud
Dec 3, 2014·Journal of the American Academy of Dermatology·Martina SanlorenzoSusana Ortiz-Urda
Jan 8, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alexandre ChanMario E Lacouture
Feb 3, 2015·Therapeutic Advances in Drug Safety·Gordon Mallarkey, Arduino A Mangoni
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Sarah J Welsh, Pippa G Corrie
Jun 17, 2015·Journal of Ophthalmic Inflammation and Infection·Dafina DraganovaFrançois Willermain
Jul 24, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ravi K AmaravadiAntonia R Sepulveda
Oct 28, 2015·Journal of Surgical Oncology·Devin C FlahertyMark B Faries
Jan 19, 2016·Oncology Reviews·Nuri Faruk Aykan
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Georgina V LongKeith T Flaherty
Feb 3, 2016·Japanese Journal of Clinical Oncology·Hideyuki Akaza
Oct 7, 2016·British Journal of Cancer·Matteo S CarlinoPaolo A Ascierto
Jul 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U Urner-BlochS M Goldinger

❮ Previous
Next ❯

Citations

Oct 27, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivek SubbiahBhumsuk Keam
Jul 26, 2018·Plastic and Reconstructive Surgery·Thomas KnackstedtBrian Gastman
Jan 18, 2018·Journal of Neuro-oncology·Benjamin BelandGarnette Sutherland
Jan 15, 2019·Future Oncology·Alice IndiniMario Mandalà
Sep 4, 2018·The Kaohsiung Journal of Medical Sciences·Shu-Yun Yang, San-Ni Chen
Oct 17, 2019·Photodermatology, Photoimmunology & Photomedicine·Markus V HepptMarkus Reinholz
Nov 14, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Laura von DückerDo Ro Thée Nashan
Oct 1, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O MichielinUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
May 17, 2019·Melanoma Research·Nadim MouradUNKNOWN PATIO group
Jun 20, 2020·International Journal of Cancer. Journal International Du Cancer·Michiel C T van ZeijlMichel W J M Wouters
Aug 28, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·I Torres-NavarroR Botella-Estrada
Apr 13, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Katharina C Kähler
Jun 28, 2019·Therapeutic Advances in Medical Oncology·Michel DucreuxMaximiliano Gelli
Apr 5, 2020·International Journal of Molecular Sciences·Jingxuan ZhuWeiwei Han
Sep 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark W KieranJames A Whitlock
Apr 18, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Justine V Cohen, Ryan J Sullivan
Oct 28, 2020·Molecular Cancer Research : MCR·Hideki TeraiKoichi Fukunaga
Oct 26, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Joyce van SluisRonald Boellaard
Oct 24, 2020·Cancers·Lukasz KurykMariangela Garofalo
Mar 5, 2020·Gynecologic Oncology Reports·Serena CappuccioGiovanni Scambia
Apr 5, 2021·Bulletin du cancer·Vincent SibaudGabriel Perlemuter
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O MichielinUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Apr 30, 2021·Italian Journal of Dermatology and Venereology·Riccardo PampenaCaterina Longo
Mar 14, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Denise CaseyHarpreet Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.